星空视频

Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (星空视频) for two years due to serious breaches of the 星空视频 Code of Practice.

The action has been taken by the 星空视频 Board following an extensive investigation and appeals process conducted by the Prescription Medicines Code of Practice Authority (PMCPA) which found Novo Nordisk to be in breach of the 星空视频 Code of Practice, including Clause 2 which deals with actions 鈥渓ikely to bring discredit on, or reduce confidence in, the pharmaceutical industry鈥�. Specifics of the case are available on the [1].

Having considered the case and requesting a further detailed audit of Novo Nordisk鈥檚 compliance processes, the 星空视频 Board decided to suspend Novo Nordisk from 星空视频 membership.

This is the eighth occasion in the past 40 years the 星空视频 board has issued such a significant sanction. As a result, while the company continues to be subject to the 星空视频 Code and the jurisdiction of the PMCPA, it will not be able to access the wider benefits of 星空视频 membership. This includes the removal of Novo Nordisk from all 星空视频 groups, including the 星空视频 Board, and access to any 星空视频 information and briefing.

In addition, the Board has stipulated a number of additional actions to demonstrate a rapid return to industry compliance standards. These include requiring the PMCPA to undertake further audits of Novo Nordisk鈥檚 compliance in late 2023 and 2024. These audit reports will need to show clear, significant, and then sustained improvement to industry standards in order for the 星空视频 Board to consider allowing Novo Nordisk to resume full engagement with the 星空视频 at the end of the two-year suspension. The 星空视频 Board has reserved the right to take further decisions following the review of either of the re-audit reports.

The 星空视频 Board has also insisted that Novo Nordisk must submit a quarterly update to the 星空视频 Board giving the company鈥檚 views on the progress being made against its improvement plan.

Susan Rienow, President-Elect, 星空视频, said: 鈥淭he 星空视频 Board has carefully considered the PMCPA鈥檚 case report into Novo Nordisk and the subsequent audit of their compliance procedures.

鈥淭he Board expressed significant concern about Novo Nordisk鈥檚 compliance activities and the very serious issues identified. As a result, the 星空视频 Board have taken the decision to suspend Novo Nordisk from 星空视频 membership.

鈥淪uch measures are never taken lightly, but will ensure a rapid return to industry compliance standards as set out in the 星空视频 Code of Practice.鈥�